Glycemic control in diabetic patients treated with Sitagliptin in a single tertiary centre

Background Sitagliptin is a DPP-IV inhibitor and has been proven to reduce HbA1c by 0.8% when used as monotherapy and up to 2.1% when used in combination with maximum dose of metformin. Objectives To evaluate the glycemic control in patients treated with sitagliptin either as monotherapy or as...

Full description

Bibliographic Details
Main Authors:	WS, Wan Juani, M., Azura Dina, S., Norlela, M., Norlaila, AW, Norasyikin, O, Ahmad Marzuki, R, Subashini, Loh, Huai Heng, Shahar, Mohammad Arif, O, Mohd Rahman, K., Nor Azmi
Format:	Article
Language:	English
Published:	Malaysian Endocrine and Metabolic Society 2014
Subjects:	R Medicine (General) RC Internal medicine
Online Access:	http://irep.iium.edu.my/50065/ http://irep.iium.edu.my/50065/ http://irep.iium.edu.my/50065/4/OP-37.pdf

id	iium-50065
recordtype	eprints
spelling	iium-500652018-06-20T00:40:05Z http://irep.iium.edu.my/50065/ Glycemic control in diabetic patients treated with Sitagliptin in a single tertiary centre WS, Wan Juani M., Azura Dina S., Norlela M., Norlaila AW, Norasyikin O, Ahmad Marzuki R, Subashini Loh, Huai Heng Shahar, Mohammad Arif O, Mohd Rahman K., Nor Azmi R Medicine (General) RC Internal medicine Background Sitagliptin is a DPP-IV inhibitor and has been proven to reduce HbA1c by 0.8% when used as monotherapy and up to 2.1% when used in combination with maximum dose of metformin. Objectives To evaluate the glycemic control in patients treated with sitagliptin either as monotherapy or as add on therapy. Design and Method This was a retrospective descriptive cross sectional study conducted from January 2014 till April 2014 involving type 2 diabetec patients treated with sitagliptin in UKMMC. Data were retrieved from electronic medical record and their fasting blood sugar and HbA1c at initiation of treatment and the following visit were analyzed. Results A total of 212 patients received Sitagliptin in our centre. Median duration of follow-up after initiation of Sitaglitin is 5.8 months (2.2,9.1). The median overall FBS at initiation of therapy was 8.4mmol/l (7, 10.1) and at follow up was 8mmol/l (6.2, 9.4) (p <0.05). The mean overall HbA1c at initiation of therapy was 8.2% (7.4, 9.2) and at follow up was 7.5% (6.8, 8.4) (p < 0.01). Eight (3.8%) patients received Sitagliptin as monotherapy, 51 (24%) received as dual oral therapy, 91 (42.9%) as triple oral therapy and 6 (2.8%) as fourth oral agents. Twenty-six (12.3%) received Sitagliptin in combination with other oral agents with basal insulin, 19 (9%) in combination with or without metformin and premixed insulin, 11 (5.2%) in combination with or without metformin and basal bolus insulin. The mean HbA1c at pre and post therapy, for those on monotherapy were 7.2% and 6.8% (p=0.205) respectively; dual oral therapy were 7.5% and 6.9% ( p =0.017), triple oral therapy 8.0% and 7.4% (p=0.001), quadruple oral therapy 8.3% and 7.6% (p=0.069), in combination with basal insulin 8.8% and 8.0% (p=0.045) , in combination with premixed insulin 9.9% and 8.2% (p=0.001), and in combination with basal bolus insulin was 9.1% and 8.8% (p=0.05) . Conclusions Significant HbA1c reductions were seen when Sitagliptin was given as dual or triple oral therapy with greatest reduction observed when it was added to premixed insulin treatment. Malaysian Endocrine and Metabolic Society 2014-05 Article PeerReviewed application/pdf en http://irep.iium.edu.my/50065/4/OP-37.pdf WS, Wan Juani and M., Azura Dina and S., Norlela and M., Norlaila and AW, Norasyikin and O, Ahmad Marzuki and R, Subashini and Loh, Huai Heng and Shahar, Mohammad Arif and O, Mohd Rahman and K., Nor Azmi (2014) Glycemic control in diabetic patients treated with Sitagliptin in a single tertiary centre. Journal of Endocrinology and Metabolism, 4 (1(Sup)). p. 17. ISSN 2229-9572 http://www.jmems.org/index.php/jmems/issue/view/5
repository_type	Digital Repository
institution_category	Local University
institution	International Islamic University Malaysia
building	IIUM Repository
collection	Online Access
language	English
topic	R Medicine (General) RC Internal medicine
spellingShingle	R Medicine (General) RC Internal medicine WS, Wan Juani M., Azura Dina S., Norlela M., Norlaila AW, Norasyikin O, Ahmad Marzuki R, Subashini Loh, Huai Heng Shahar, Mohammad Arif O, Mohd Rahman K., Nor Azmi Glycemic control in diabetic patients treated with Sitagliptin in a single tertiary centre
description	Background Sitagliptin is a DPP-IV inhibitor and has been proven to reduce HbA1c by 0.8% when used as monotherapy and up to 2.1% when used in combination with maximum dose of metformin. Objectives To evaluate the glycemic control in patients treated with sitagliptin either as monotherapy or as add on therapy. Design and Method This was a retrospective descriptive cross sectional study conducted from January 2014 till April 2014 involving type 2 diabetec patients treated with sitagliptin in UKMMC. Data were retrieved from electronic medical record and their fasting blood sugar and HbA1c at initiation of treatment and the following visit were analyzed. Results A total of 212 patients received Sitagliptin in our centre. Median duration of follow-up after initiation of Sitaglitin is 5.8 months (2.2,9.1). The median overall FBS at initiation of therapy was 8.4mmol/l (7, 10.1) and at follow up was 8mmol/l (6.2, 9.4) (p <0.05). The mean overall HbA1c at initiation of therapy was 8.2% (7.4, 9.2) and at follow up was 7.5% (6.8, 8.4) (p < 0.01). Eight (3.8%) patients received Sitagliptin as monotherapy, 51 (24%) received as dual oral therapy, 91 (42.9%) as triple oral therapy and 6 (2.8%) as fourth oral agents. Twenty-six (12.3%) received Sitagliptin in combination with other oral agents with basal insulin, 19 (9%) in combination with or without metformin and premixed insulin, 11 (5.2%) in combination with or without metformin and basal bolus insulin. The mean HbA1c at pre and post therapy, for those on monotherapy were 7.2% and 6.8% (p=0.205) respectively; dual oral therapy were 7.5% and 6.9% ( p =0.017), triple oral therapy 8.0% and 7.4% (p=0.001), quadruple oral therapy 8.3% and 7.6% (p=0.069), in combination with basal insulin 8.8% and 8.0% (p=0.045) , in combination with premixed insulin 9.9% and 8.2% (p=0.001), and in combination with basal bolus insulin was 9.1% and 8.8% (p=0.05) . Conclusions Significant HbA1c reductions were seen when Sitagliptin was given as dual or triple oral therapy with greatest reduction observed when it was added to premixed insulin treatment.
format	Article
author	WS, Wan Juani M., Azura Dina S., Norlela M., Norlaila AW, Norasyikin O, Ahmad Marzuki R, Subashini Loh, Huai Heng Shahar, Mohammad Arif O, Mohd Rahman K., Nor Azmi
author_facet	WS, Wan Juani M., Azura Dina S., Norlela M., Norlaila AW, Norasyikin O, Ahmad Marzuki R, Subashini Loh, Huai Heng Shahar, Mohammad Arif O, Mohd Rahman K., Nor Azmi
author_sort	WS, Wan Juani
title	Glycemic control in diabetic patients treated with Sitagliptin in a single tertiary centre
title_short	Glycemic control in diabetic patients treated with Sitagliptin in a single tertiary centre
title_full	Glycemic control in diabetic patients treated with Sitagliptin in a single tertiary centre
title_fullStr	Glycemic control in diabetic patients treated with Sitagliptin in a single tertiary centre
title_full_unstemmed	Glycemic control in diabetic patients treated with Sitagliptin in a single tertiary centre
title_sort	glycemic control in diabetic patients treated with sitagliptin in a single tertiary centre
publisher	Malaysian Endocrine and Metabolic Society
publishDate	2014
url	http://irep.iium.edu.my/50065/ http://irep.iium.edu.my/50065/ http://irep.iium.edu.my/50065/4/OP-37.pdf
first_indexed	2023-09-18T21:10:45Z
last_indexed	2023-09-18T21:10:45Z
_version_	1777411235547971584

Glycemic control in diabetic patients treated with Sitagliptin in a single tertiary centre

Similar Items